Chenpon Pharmaceutical clinical trials
The registry lists 3 studies whose lead sponsor is Chenpon Pharmaceutical or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 8, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 3studies on the registry
- 0open to participants now
Pipeline: 4 programmes
Each counted once: 4 with a study Chenpon Pharmaceutical leads registered in the last two years.
The 2 phase-3 programmes — sign in to see them, free: with every programme, filter by condition or phase and sort by first study or primary completion.
The 4 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
New in the registry
A programme's first Chenpon Pharmaceutical study in the last 90 days, by the day it was submitted.
- Aug 31umeclidinium bromide · Pulmonary Disease, Chronic ObstructivePhase 2
- Aug 31Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol · AsthmaPhase 1
- Aug 24Budesonide · AsthmaPhase 3
- Aug 24formoterol · AsthmaPhase 3
Moved up a phase
Chenpon Pharmaceutical's first study at a higher phase in the last 90 days, of a programme already under way.
None in the last 90 days.
Companies developing a programme in the same conditions as Chenpon Pharmaceutical’s (1 condition its studies of the last two years are mainly about), ranked by how directly they meet: a programme tested against the other’s drug, read from the study’s arms; then the conditions where both are in phase 3; then the conditions shared. Size plays no part.
- AstraZeneca1 condition shared: Asthma
- Chiesi Farmaceutici S.p.A.1 condition shared: Asthma
- GlaxoSmithKline1 condition shared: Asthma
- Jiangsu HengRui Medicine Co., Ltd.1 condition shared: Asthma
- Pfizer1 condition shared: Asthma
| Company | Conditions shared | Their phase 3 there | Where they meet, by arms |
|---|---|---|---|
| AstraZeneca8 programmes in shared conditions | 1Asthma | benralizumab, tezepelumab, BFF MDI | no study of one against the other’s drug |
| Chiesi Farmaceutici S.p.A.8 programmes in shared conditions | 1Asthma | CHF5993, CHF5993 100/6/12.5 μg pMDI HFA-152a, Experimental: Participant Group CHF 5993 pMDI HFA-152a | no study of one against the other’s drug |
| GlaxoSmithKline5 programmes in shared conditions | 1Asthma | felcorekibart, HFA-152a, norflurane +1 | no study of one against the other’s drug |
| Jiangsu HengRui Medicine Co., Ltd.4 programmes in shared conditions | 1Asthma | SHR-1905 | no study of one against the other’s drug |
| Pfizer2 programmes in shared conditions | 1Asthma | tilrekimig | no study of one against the other’s drug |
38 more companies — sign in to see them all, free.
Also leading studies of the same drugs, not counted as competitors (a partner, a licensee, a biosimilar maker, or a combination study): AstraZeneca (Budesonide, formoterol).
“Registry” is the highest phase of Chenpon Pharmaceutical’s own registered studies; Chenpon Pharmaceutical’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Chenpon Pharmaceutical’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Budesonide1 in phase 30 open · 1
- 0 open · 1
- formoterol1 in phase 30 open · 1
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed3100%
Over the years
- 224
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chenpon Pharmaceutical.
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.3 studies →Acquired
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 3 of 3.
- Efficacy and Safety of CP006 Inhalation Powder in Participants With AsthmaCompletedNCT07807007Phase 2
Sponsor listed in the registry: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. · Shanghai Xin Huanghe Pharmaceutical Co., Ltd. — acquired company within the Chenpon Pharmaceutical group
- Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy ParticipantsCompletedNCT07804303Phase 1
Sponsor listed in the registry: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. · Shanghai Xin Huanghe Pharmaceutical Co., Ltd. — acquired company within the Chenpon Pharmaceutical group
- Budesonide/Formoterol Inhalation Powder in Adults With AsthmaCompletedNCT07790159Phase 3
Sponsor listed in the registry: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. · Shanghai Xin Huanghe Pharmaceutical Co., Ltd. — acquired company within the Chenpon Pharmaceutical group